

CRO Communiqué
Keeping you informed about CRO progress
May 2013

Top Enrolling Physicians for April 2013

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits
Dr. Bonebrake	7	3.3	3	6.3
Dr. Carlson	5	1.3	3.5	4.8
Dr. Croy	1	1	0	1
Dr. Ellis	2	1	1.8	2.8
Dr. Goodwin	1	1.3	0	1.3
Dr. Govinda	1	1	0.5	1.5
Dr. Holden	1	1	0	1
Dr. Vu	1	1	0.5	1.5
TOTALS	19	10.9	9.3	20.2

We earned 10.9 treatment credits and 9.3 control credits this month. With one month left in this grant year, we have earned 88.9 treatment credits and 95.8 control credits. Good news is we have exceeded our NCI target for control credit of 80 for this grant year by 15.8 already. YEA! We need to earn 21.1 more treatment credits to meet the NCI target of 110 for the year. We are doing very well! Thanks to all of you for enrolling your patients on clinical trials.

NCI 9-month Accruals for Grant Year 2012-2013

Below is a chart of the NCI 9-month accrual statistics (June 2012 – February 2012) for all CCOPs. At the end of February we were at 85.3% in meeting our treatment credits of 82.5 and at 123.8% in meeting our cancer control credits of 60 for 9 months. GREAT JOB!!

Achievement of 9-mo Treatment

Accrual Goals 65 CCOP/MCCOPs - Range = 0% -158%

Number of CCOPs/MCCOPs (%)	Percentage of 9-month goal achieved
16(25%)	95 - ≥ 100%
19(29%) *CRO 85.3%	76 – 94%
13(20%)	51 – 75%
13 (20%)	26 – 50%
4 (6%)	≤ 10 – 25%

Achievement of 9-mo Cancer Control

Accrual Goals 65 CCOP/MCCOPs - Range= 0% - 161%

Number of CCOPs/MCCOPs (%)	Percentage of 9-month goal achieved
20(31%) * (CRO 123.8%)	95 - ≥ 100%
15 (23%)	76 – 94%
18 (28%)	51 – 75%
7 (11%)	26 – 50%
5 (8%)	≤ 10 – 25%

New CRO Principal Investigator

It was with great pleasure CRO announced Jay Carlson, DO accepted the position of Principal Investigator for Cancer Research for the Ozarks and Al Bonebrake, MD accepted the position of Associate Principal Investigator. Dr. Bonebrake and Dr. Carlson have a great interest in research and have been supporters of CRO. We are confident their knowledge and dedication to cancer research will lead us forward as we embrace future opportunities.

Farwell for Dr. Carolla

We are very grateful to Dr. Carolla and Dr. Roger Holden for the inspiring leadership they have provided for CRO the past five years. Their great dedication to research and years of exceptional leadership have been instrumental in the success of CRO and in bringing other CCOP's to seek us out. CRO will host a farewell party for Dr. Carolla on Thursday, May 30th from 5p to 6:30p at Touch restaurant. Please plan to attend.

New CRO Affiliations

Next Wednesday, May 8th Dr. Lyss, PI and Jean Roark, Administrator at the Heartland CCOP in St. Louis will be visiting with us to discuss collaboration. We continue to work to add Mercy St. Louis and Good Samaritan in Mt. Vernon, Illinois to become CRO affiliates. May 31, 2013 is the date for this merger to officially take place.

NCI's CIRB

On April 16, 2013 CRO received notification of having been accepted as a member of NCI's CIRB. We are awaiting a letter from the CIRB confirming completion of all transition activities and when we may begin to open studies using the CIRB. The NCI's CIRB is currently approving only Phase III studies. CoxHealth and Mercy Springfield IRB's will continue to be the IRB for Phase II NCI studies, all trials from cooperative groups MDAnderson, SunCoast, Wake Forest and all industrial trials.

New Studies Approved in April, 2013
Opened at Cox and Mercy Springfield

Alliance N0877 Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

SWOG S0806 A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)

Studies Permanently Closed to Enrollment at Cox & Mercy in April 2013

ECOG E1908 A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab

MDA 2009-0288 POWER Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients

Studies Temporally Closed to Enrollment at Cox & Mercy in April 2013

SWOG S0709 A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (PS-2) Selected by Serum Proteomics